Ensysce Biosciences, Inc. (ENSC): Nasdaq/NYSE listing notice — Ensysce Biosciences receives Nasdaq delisting notice for MVLS non-compliance

Ensysce Biosciences, Inc.

Nasdaq notified Ensysce on Dec 14, 2022, that it failed to regain compliance with $35M minimum value of listed securities (MVLS) requirement.
Company had until Dec 13, 2022 to meet MVLS rule; failed to do so, triggering delisting process.
Ensysce will timely request a hearing before Nasdaq Hearings Panel to stay delisting.
Panel may grant extension up to June 12, 2023, but no assurance of success or continued listing.
Common stock (ENSC) and warrants (ENSCW) trading subject to potential suspension.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Ensysce Biosciences, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

(the “ June 16 th Notice ”). The June 16 th Notice stated that the Company’s Minimum Value of Listed Securities (“ MVLS ”) for the preceding 30 consecutive business days was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq listing rule 5550(b)(2) and that the Company had until December 13, 2022, to regain compliance. The Notice states that the Company has not regained compliance with the MVLS requirement within the period provided and that the securities of the Company would be subject to delisting unless the Company timely reques

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-035782

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.